Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neumora Therapeutics Inc.
Headquarters: Watertown, MA, United States of America
Website: http://www.neumoratx.com
Year Founded: 2019
Status: Public
Industry Sector: HealthTechnology
CEO: Paul L. Berns
Number Of Employees: 110
Enterprise Value: $1,382,458,200
PE Ratio: -0.56
Exchange/Ticker 1: NASDAQ:NMRA
Exchange/Ticker 2: N/A
Latest Market Cap: $137,520,208
BioCentury | Apr 4, 2025
Finance
1Q25 Wrap: Market backslide hits broad swath of companies
Winners, losers in biotech stock tiers in 1Q25
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
BioCentury | Feb 14, 2025
Management Tracks
Berns becomes chairman, CEO of Neumora
Plus: Robin Kenselaar named chief commercial officer at Orchard, and an update from Bluejay
BioCentury | Jan 31, 2025
Product Development
Precision neuropsychiatry spotlight: a BioCentury podcast
Plus: Insights from Icon’s Peter Schueler on the ECNP Roadmap Meeting on Precision Psychiatry
BioCentury | Jan 7, 2025
Product Development
Biotech in the New Year. Plus: Beyond Biosecure
Picks, perils and predictions for biopharma in 2025 — the latest BioCentury podcast
BioCentury | Jan 2, 2025
Product Development
Neumora’s prospects dim for κ-opioid program after first Phase III readout
Two more studies of navacaprant underway as company considers possible female-only effect
BioCentury | Dec 14, 2024
Management Tracks
Gilead hires Dietmar Berger as CMO
Plus: Tanya Wallace to head of neuroscience and ophthalmology at AbbVie, and updates from Editas and Zentalis
BioCentury | Nov 11, 2024
Product Development
AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline
Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question
BioCentury | Nov 6, 2024
Product Development
Two upcoming readouts could shape the market for κ-opioid antidepressants
Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia
BioCentury | Sep 27, 2024
Market Access
BMS’s new schizophrenia drug has big potential, but won’t be an overnight success
Market access and indication expansion will gate Cobenfy’s ability to help fill the pharma’s major revenue holes
Items per page:
1 - 10 of 32